Christopher Heaphy, PhD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

PhD, University of New Mexico School of Medicine

Dr. Christopher Heaphy is a cancer biologist that has been conducting basic and translational studies focused on elucidating the role of telomere alterations across a range of cancer types (e.g. prostate, breast, brain, pancreatic, ovarian). Overall, his research program uses a combination of tissue-based, cell-based, and molecular approaches to study normal and abnormal telomere biology as it relates to cancer initiation and progression, with a particular interest in the Alternative Lengthening of Telomeres (ALT) phenotype – a telomerase-independent telomere maintenance mechanism. In addition, his laboratory focuses on how these findings may be readily translated into accurately predicting cancer risk, early detection, prognosis, and potential response to targeted therapies. Dr. Heaphy received his Ph.D. from the University of New Mexico School of Medicine and did his postdoctoral training at the Johns Hopkins University School of Medicine. He is currently affiliated with Boston Medical Center and is a member of the Boston University-Boston Medical Center (BU-BMC) Cancer Center.

Boston University
BU-BMC Cancer Center

Boston University
Evans Center for Interdisciplinary Biomedical Research

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences

2021 Shipley Prostate Cancer Research Center at BU: Executive Advisory Committee Member
2021 North American Neuroendocrine Tumor Society (NANETS): Co-Chair of the Scientific Review & Research Committee
2021 Boston University: CTSI Pilot Grant Awardee
2020 BU-BMC Cancer Center: American Cancer Society BU-BMC Cancer Center Pilot and Feasibility Program Awardee
2020 Boston University School of Medicine: Shipley Prostate Cancer Pilot Grant Awardee
2019 95th Annual American Association of Neuropathologists Meeting: Moore Award for the Best Clinico-Pathologic Paper in Neuropathology
2016 North American Neuroendocrine Tumor Society: Basic/Translational Science Investigator Award
2014 Patrick C. Walsh Prostate Cancer Research Fund: Dr. and Mrs. Peter S. Bing Scholar Award
2014 Prostate Cancer Foundation: Young Investigator Award
2013 Johns Hopkins Department of Pathology Young Investigator’s Day: Award for Excellence in Translational Research
2012 Johns Hopkins Fellow Research Day: 1st Place for Basic Research
2011 Johns Hopkins Department of Pathology Young Investigator’s Day: Award for Excellence in Translational Research
2011 United States and Canadian Academy of Pathology: Stowell-Orbison Award
2002 National Cancer Institute: Cancer Research Training Fellowship; Laboratory of Cellular Carcinogenesis and Tumor Promotion

Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy
01/01/2021 - 12/31/2021 (PI)
Johns Hopkins University National Cancer Inst


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Dreijerink KM, Hackeng WM, Singhi AD, Heaphy CM, Brosens LA. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors. J Pathol. 2022 Feb; 256(2):143-148. PMID: 34750813
  2. Shrestha E, Coulter JB, Guzman W, Ozbek B, Hess MM, Mummert L, Ernst SE, Maynard JP, Meeker AK, Heaphy CM, Haffner MC, De Marzo AM, Sfanos KS. Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer. Proc Natl Acad Sci U S A. 2021 08 10; 118(32). PMID: 34341114; PMCID: PMC8364155; DOI: 10.1073/pnas.2018976118;
  3. Heaphy CM, VandenBussche CJ. Prognostic biomarkers in pancreatic neuroendocrine tumors. Cancer Cytopathol. 2021 Nov; 129(11):841-843. PMID: 34242496
  4. Kang HJ, Oh JH, Kim YW, Kim W, An J, Sung CO, Kim J, Shim JH, Hwang S, Yu E, Heaphy CM, Hong SM. Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. Liver Int. 2021 10; 41(10):2499-2510. PMID: 34036718
  5. Brosnan-Cashman JA, Davis CM, Diplas BH, Meeker AK, Rodriguez FJ, Heaphy CM. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. Mod Pathol. 2021 10; 34(10):1810-1819. PMID: 34103668
  6. Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2021 Apr 13. PMID: 33849943; PMCID: PMC8511349; DOI: 10.1136/gutjnl-2020-322595;
  7. Hempel Sullivan H, Maynard JP, Heaphy CM, Lu J, De Marzo AM, Lotan TL, Joshu CE, Sfanos KS. Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes. J Pathol. 2021 04; 253(4):415-426. PMID: 33338262
  8. Joshu CE, Heaphy CM, Barber JR, Lu J, Zarinshenas R, Davis C, Han M, Lotan TL, Sfanos KS, De Marzo AM, Meeker AK, Platz EA. Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer. Cancer Prev Res (Phila). 2021 04; 14(4):463-470. PMID: 33355185; PMCID: PMC8026488; DOI: 10.1158/1940-6207.CAPR-20-0250;
  9. Pieterman CRC, Sadowski SM, Maxwell JE, Katz MHG, Lines KE, Heaphy CM, Tirosh A, Blau JE, Perrier ND, Lewis MA, Metzcar JP, Halperin DM, Thakker RV, Valk GD. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. Endocr Relat Cancer. 2020 08; 27(8):T9-T25. PMID: 32069215
  10. Hackeng WM, Schelhaas W, Morsink FHM, Heidsma CM, van Eeden S, Valk GD, Vriens MR, Heaphy CM, Nieveen van Dijkum EJM, Offerhaus GJA, Dreijerink KMA, Brosens LAA. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas. Endocr Pathol. 2020 Jun; 31(2):108-118. PMID: 32103422; PMCID: PMC7250793; DOI: 10.1007/s12022-020-09611-8;
Showing 10 of 92 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 92 publications over 18 distinct years, with a maximum of 11 publications in 2020

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Alternative lengthening of telomeres
Tissue-based biomarkers

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Co-Mentor or Peer Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')
  • Phone (see 'Contact Info')
Heaphy's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department